Aurobindo Pharma Limited has announced its financial results for the quarter and fiscal year ended March 31, 2026. The company reported strong year-on-year growth, with a standalone annual profit of ₹24,148.0 million. Additionally, the company disclosed key changes in its auditing team and confirmed the successful completion of its share buyback program, reinforcing its commitment to shareholder value and long-term financial stability.
Annual Financial Performance
For the financial year ended March 31, 2026, Aurobindo Pharma achieved standalone revenue from operations of ₹1,11,717.2 million, compared to ₹1,09,333.0 million in the previous year. The standalone net profit after tax rose to ₹24,148.0 million, demonstrating significant growth from ₹17,467.9 million in FY 2025. On a consolidated basis, the Group performed strongly, reporting an annual profit after tax of ₹35,029.7 million.
Share Buyback Completion
The company successfully executed a buyback of 5,423,728 fully paid-up equity shares. This program, approved by the Board on April 06, 2026, represented 0.93% of the total equity shares. The buyback was concluded with a total consideration of ₹8,000.0 million paid to eligible shareholders on May 07, 2026.
Changes in Auditing Leadership
In a move to streamline corporate governance, the company announced the resignation of M/s. MRR & Associates as Secretarial Auditors, effective May 22, 2026, due to health concerns of the proprietor. Simultaneously, the Board has appointed M/s. RPR & Associates as the new Secretarial Auditors for a term of five consecutive years, starting from the 2026-27 fiscal year, subject to shareholder approval. Furthermore, the company has re-appointed M/s. Ernst & Young LLP to serve as Internal Auditors for the period from June 2026 to May 2027.
Strategic Acquisitions and Business Transfers
The Group continues to expand its footprint and internal capabilities. Notably, the company finalized a business transfer agreement on January 01, 2026, to acquire a non-oncology prescription formulations business for a total consideration of ₹3,250 million. This strategic acquisition is part of the company’s broader effort to consolidate its market position and optimize its pharmaceutical product portfolio.
Source: BSE
